Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20

You may also be interested in...



Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study

PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis

Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study

PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis

Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol

PERTH, Australia - Sydney-based Pharmaxis is breathing easier following a positive recommendation from U.S. FDA's Pulmonary-Allergy Drugs Advisory Committee Nov. 20 for approval of its bronchial test Aridol

Related Content

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel